Biganib is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to Crizotinib.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Non-small cell lung cancer (NSCLC) is a type of lung cancer that occurs when abnormal cells form and multiply in lung tissues. It is one of the two main types of lung cancer, with the other being small-cell lung cancer. NSCLC is further categorized into three main types:
Other less common subtypes of NSCLC include sarcomatoid carcinoma and adenosquamous carcinoma.
Prevalence: NSCLC is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases.
Symptoms: Common symptoms of NSCLC include:
Some cases may be asymptomatic and discovered during routine screenings.
Risk Factors:
Diagnosis: Diagnosis involves a series of tests, including physical examination, laboratory tests, imaging (X-rays, CT scans), biopsy, and other procedures like bronchoscopy or thoracentesis.
Staging: Staging determines the extent of cancer spread and includes stages 0 to IV:
Treatment: Treatment options depend on the stage and type of NSCLC and may include:
Recovery time varies, and the prognosis is influenced by factors such as stage, type, and overall health.
Prevention: While NSCLC cannot always be prevented, reducing risk factors like smoking can significantly lower the risk. Early detection through screenings is crucial for better outcomes.
The prognosis for NSCLC varies based on factors like stage, type, and overall health. Early detection and treatment improve the chances of a cure, and even in cases where a cure is not possible, managing symptoms can lead to a fulfilling life. Survival rates are estimates, and individual responses to treatment may differ. Consultation with a healthcare provider provides more personalized information.
The safety and efficacy of Brigatinib in pediatric patients have not been established.
Hypersensitivity: Contraindicated in patients with known hypersensitivity to Brigatinib or any other components.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Disposal of medications is crucial to prevent accidental ingestion by pets, children, or others and to avoid environmental contamination.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.